A case of ameloblastic carcinoma containing melanocyte and melanin in a 66-year-old male with swelling and an ulcerating firm mass in the left submandibular region is presented. The diagnosis was confirmed by biopsy. The current histopathological diagnosis and management are discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1600-0714.2005.00306.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trends in Research of Odontogenic Keratocyst and Ameloblastoma.
J Dent Res
January 2025
State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan, China.
Odontogenic keratocyst (OKC) and ameloblastoma (AM) are common jaw lesions with high bone-destructive potential and recurrence rates. Recent advancements in technology led to significant progress in understanding these conditions. Single-cell and spatial omics have improved insights into the tumor microenvironment and cellular heterogeneity in OKC and AM.
View Article and Find Full Text PDFDifference in survival and prognosis between malignant tumors of odontogenic origin.
J Stomatol Oral Maxillofac Surg
November 2024
Sorbonne Université, Paris, France; Department of Maxillo-Facial Surgery, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France; Sorbonne université, INSERM UMRS 938, Centre de Recherche de Saint Antoine, Team Cancer Biology and Therapeutics, France.
Introduction: The prognosis of metastatic ameloblastoma (METAM), now defined as a benign tumor, and malignant odontogenic tumors (MOT) is poorly studied in the literature. The aim of this study was to determine the prognosis and factors influencing the survival of these patients.
Material And Methods: Using the SEER database, we retrieved clinical data of patients with malignant tumors of dental origin between 1975 and 2020.
Surrogate Immunohistochemical Markers of Proliferation and Embryonic Stem Cells in Distinguishing Ameloblastoma from Ameloblastic Carcinoma.
Head Neck Pathol
October 2024
Department of Oral and Maxillofacial Pathology, Faculty of Health Sciences, University of Pretoria, Pretoria Oral Health Care Centre, Office 6-11, Corner of Steve Biko and Dr Savage Roads, Pretoria, 0084, South Africa.
Purpose: The current study aimed to investigate the use of surrogate immunohistochemical (IHC) markers of proliferation and stem cells to distinguish ameloblastoma (AB) from ameloblastic carcinoma (AC).
Methods: The study assessed a total of 29 ACs, 6 ABs that transformed into ACs, and a control cohort of 20 ABs. The demographics and clinicopathologic details of the included cases of AC were recorded.
Epidemiology of odontogenic tumours and selected cysts diagnosed at a single New Zealand oral pathology centre- A 15-year retrospective study.
Oral Maxillofac Surg
December 2024
Department of Oral Diagnostic and Surgical Sciences, University of Otago, Dunedin, New Zealand.
Article Synopsis
- The research analyzed the occurrence of odontogenic tumors (OT) and certain cysts at an oral pathology center in New Zealand over 15 years, revealing that 1.8% of biopsies were identified as these conditions.
- The most common types identified were odontoma, ameloblastoma, and cemento-ossifying fibroma, with male patients and those diagnosed in the mandibular region being more prevalent.
- The study highlighted the importance of long-term monitoring for patients with OKC and ameloblastoma due to their recurrence rates of 15.2% and 13.7%, respectively.
Differential Expression of Immunohistochemical Markers in Ameloblastoma & Ameloblastic Carcinoma: A Systematic Review and Meta-analysis of observational studies.
F1000Res
July 2024
Department of Dentistry, Oral Health Institute, Hamad Medical Corporation, Doha, Doha, Qatar.
Background: Differentiating between ameloblastoma (AB) and ameloblastic carcinoma (AC) is difficult, especially when AB has atypical cytological characteristics or an uncommon clinical history. This systematic review and meta-analysis aimed to elucidate the differential expression of immunohistochemical markers between AB and AC.
Methods: We conducted a thorough search of PUBMED and SCOPUS according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify cross-sectional studies that compared the expression of immunohistochemical markers in AB and AC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!